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Abstract
Background:  European and Developing Countries Clinical Trials Partnership (EDCTP) was
founded in 2003 by the European Parliament and Council. It is a partnership of 14 European Union
(EU) member states, Norway, Switzerland, and Developing Countries, formed to fund acceleration
of new clinical trial interventions to fight the human immunodeficiency virus and acquired immune
deficiency syndrome (HIV/AIDS), malaria and tuberculosis (TB) in the sub-Saharan African region.
EDCTP seeks to be synergistic with other funding bodies supporting research on these diseases.
Methods: EDCTP promotes collaborative research supported by multiple funding agencies and
harnesses networking expertise across different African and European countries. EDCTP is
different from other similar initiatives. The organisation of EDCTP blends important aspects of
partnership that includes ownership, sustainability and responds to demand-driven research. The
Developing Countries Coordinating Committee (DCCC); a team of independent scientists and
representatives of regional health bodies from sub-Saharan Africa provides advice to the
partnership. Thus EDCTP reflects a true partnership and the active involvement and contribution
of these African scientists ensures joint ownership of the EDCTP programme with European
counterparts.
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Results:  The following have been the major achievements of the EDCTP initiative since its
formation in 2003; i) increase in the number of participating African countries from two to 26 in
2008 ii) the cumulative amount of funds spent on EDCTP projects has reached € 150 m, iii) the
cumulative number of clinical trials approved has reached 40 and iv) there has been a significant
increase number and diversity in capacity building activities.
Conclusion: While we recognise that EDCTP faced enormous challenges in its first few years of
existence, the strong involvement of African scientists and its new initiatives such as unconditional
funding to regional networks of excellence in sub-Saharan Africa is envisaged to lead to a
sustainable programme. Current data shows that the number of projects supported by EDCTP is
increasing. DCCC proposes that this success story of true partnership should be used as model by
partners involved in the fight against other infectious diseases of public health importance in the
region.
Background
Tuberculosis, human immunodeficiency virus (HIV) and
malaria cross paths in sub-Saharan Africa, the epicentre of
the three infections. Although HIV/AIDS, tuberculosis
(TB) and malaria are three treatable and preventable dis-
eases, they are having a devastating impact in the world's
poorest countries. Sub-Saharan Africa has just over 10%
of the world's population but accounts for 90% of malaria
deaths, two-thirds of all people living with HIV, and
nearly one-third of all TB cases [1]. The human impact of
these three diseases is undeniable, but their social and
economic impacts are also severe. Thus investments in the
fight against HIV/AIDS, tuberculosis and malaria will lead
to very significant improvements in health and lives of
people across sub-Saharan Africa.
Global resources devoted to fighting the three diseases
have been rapidly scaled up in recent years by various ini-
tiatives or programs including the World Health Organi-
zation (WHO), Tropical Diseases Research (TDR),
Foundation for Innovative New Diagnostics (FIND), the
US Centers for Disease Control and Prevention (CDC),
National Institute of Health (NIH), European Union
(EU), Wellcome Trust (WT), Multilateral Initiative on
Malaria in Africa (MIM), to mention a few. These initia-
tives have achieved significant results in the areas of
capacity building, networking, and development of new
tools for intervention. One such initiative was the forma-
tion in 2003, of the European and Developing Countries
Clinical Trials Partnership (EDCTP), a partnership of 14
European Union (EU) member states, Norway and Devel-
oping Countries, with a particular focus on sub-Saharan
African states. EDCTP was formed to develop new clinical
trial interventions to fight the human immunodeficiency
virus/acquired immune deficiency syndrome (HIV/
AIDS), malaria and tuberculosis (TB) in the sub-Saharan
region. Switzerland joined the partnership in 2006.
EDCTP has sought to be synergistic with other funding
bodies supporting research on these three diseases and
promoted collaborative research involving support from
multiple funding agencies and harnessing networking
expertise across different African and European countries
[2]. Formation of EDCTP followed an appeal from African
leaders (July 2000) [3] found in the Abuja Declaration
(April 2001) [4] that specified the need to find interven-
tions to ensure adequate and effective control of malaria,
HIV/AIDS, TB and other related infectious diseases in the
African continent. The program was adopted by the Euro-
pean Parliament and the Council in June 2003 [5]; with a
200 million Euros contribution from the European Com-
mission (EC) over 5 years, and expected matching funds
from European National Programmes and other parties
such as pharmaceutical industries. This agreement is con-
tained in Article 169 of the EC treaty that allows participa-
tion of the European Community in EU member states'
national research and development programmes [6].
The activities of EDCTP are in seven categories namely:
North-North/North-South networking, South-South
(intra sub-Saharan) networking, support to clinical trials,
support to research capacity building, advocacy and fund
raising, management and information management.
The notion of establishing and strengthening of research
capacity in developing countries adopted by EDCTP is of
prime importance in empowering these countries to find
rational and efficient solutions to their health problems
through scientific research. It is also known that institu-
tional links with other researchers in the north and south
greatly facilitate the process of research strengthening
through graduate study programs, technology transfer,
'hands-on' research training in the field, expanded net-
working with contacts of other partners and continued
scientific exchanges in the context of actual research pro-
grams [7]. In North-North and North-South networking
EDCTP aims to promote and facilitate coordination and
pooling of resources among EU states, and to form alli-
ances between European institutions and African part-
ners. Consequently, EDCTP periodically launches jointBMC Public Health 2009, 9:249 http://www.biomedcentral.com/1471-2458/9/249
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calls for grants to European National Programmes for
North-North networking, capacity building and clinical
trials programmes in Africa. Similarly, for South-South
networking EDCTP promotes and facilitates creation of
networks of African scientists and their European collabo-
rators including links with existing research networks on
the three major diseases. EDCTP's mandate is the funding
of phases II and III clinical trials although other phases
may be included in special circumstances. The emphasis
on these phases of trials is to expedite promising health
interventions from upstream research to product registra-
tion and use by public health systems in needy countries.
EDCTP works in line with science and technology strate-
gies of bodies like the EU, the New Economic Partnership
for African Development (NEPAD) and the African Union
(AU).
There is need to explain what makes EDCTP different
from other similar initiatives. We report that in the short
history of EDCTP a model of a true partnership has
emerged.
Partnership base
The governance of EDCTP has two pillars namely: the
"Partnership" and the "European Economic Interest
Group" (EEIG). The "Partnership" comprises the Partner-
ship Board (PB), the main strategic body; network of
European National Programs (ENNP); and the Develop-
ing Countries Co-coordinating Committee (DCCC). The
EEIG provides the legal, financial and operational proce-
dures to receive, dispense, account for funds and execute
actions recommended by the PB. The DCCC is a commit-
tee of African scientists and representatives of regional
health organisations from sub-Saharan Africa that focus
on clinical trials in the three major diseases. The impor-
tance of DCCC is reflected in the true value of independ-
ent scientists from sub-Saharan Africa who advise the
partnership in several aspects of its work and is an indica-
tion of the African contribution. The DCCC shapes the
research agenda according to needs and gaps in the Afri-
can region. Additional African contribution comes in
forms of study sites that have research infrastructure, per-
sonnel and leadership.
Ownership
In line with the Article 169 of the European Treaty, the
success of the EDCTP depends on a solid and sustained
collaboration of European national programmes to pro-
vide and complement the required funding. The active
involvement of African scientists and African contribution
explained above is also a sign of joint ownership of the
EDCTP programme. Although data on financial contribu-
tion from African governments, who mostly contribute
staff, infrastructure and facilitates participation of con-
senting study subjects in EDCTP funded projects, has yet
to be defined active participation by many African scien-
tists either as DCCC members or grantees is a sign that the
EDCTP programme has been embraced in sub-Saharan
Africa. The European national programmes and the study
sites in Africa are dependent on each other for success of
the programme, ensuring a joint ownership.
Capacity building
The EDCTP capacity building strategy in Africa is unique
among others in addressing the 10/90 gap [8], for exam-
ple. It offers full support only to African scientists, pro-
motes African ownership of projects, receives backing
from DCCC who have full sub-Saharan Africa regional
representation and receives scientific advice from the Part-
nership Board half of whose membership is African.
DCCC has also recently designed a strategy of uncondi-
tional funding to regional networks of excellence in sub-
Saharan Africa. These networks will comprise research
institutions with complementary research expertise that
will provide training and mentorship to less endowed
centres in their regions to bring them to levels where they
can participate more effectively in multi-centre clinical tri-
als. This will provide a conducive working environment to
health research scientists and help to retain them in the
four African regions of east, west, centre and south. In
addition, the insistence on stronger institutions building
capacity in less endowed ones within clinical trials has
helped to ensure that there is equitable distribution of
funds for capacity building in Africa.
Sustainability
We recognise that the first few years of EDCTP's existence
was full of challenges expected of any newly formed
organisation. One of these challenges manifested between
2003 and 2005 when there were rapid changes in manage-
ment of EDCTP resulting in comments that the manage-
ment structure of the organization needed to be radically
changed and that partnership with other organizations
needed to be improved [9]. However taking into consid-
eration the factors stated in the partnership and owner-
ship sections above there is currently some evidence of a
sustainable programme.
Demand-driven research
Combating the three poverty related diseases on which
EDCTP focuses is a global emergency and the world needs
quick solutions. Inevitably, since its formation, EDCTP
has been under pressure to contribute to finding these
solutions. Some authors had predicted that the EDCTP
will help to overcome the bottleneck of demonstrating a
proof of principle for promising vaccine or drug candi-
dates in testing them in early efficacy trials in endemic
areas, particularly in sub-Saharan Africa [10]. How long it
would have taken for a new organisation to reach this goal
was not conceptualised. The advertising of EDCTP with aBMC Public Health 2009, 9:249 http://www.biomedcentral.com/1471-2458/9/249
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funding of 200 million Euros from the EC and matching
funds from the European member states created a lot of
expectations. Currently available data shows that in the
past two years the situation has improved. This has
brought some discussions on how to include other dis-
eases of poverty and use the EDCTP model to address
those health problems.
New face of EDCTP
Since 2005 there have been substantial improvements in
the management and awarding of EDCTP grants. By the
end of 2007 EDCTP had funded 74 projects in 29 sub-
Saharan Africa countries. A summary of these projects are
available in EDCTP annual reports [11,12] and the
EDCTP website http://www.edcpt.org. Some key perform-
ance indicators that are transparent monitoring tools have
been used to show significant progress. Figure 1 shows the
amount of funds that have been spent on all EDCTP
projects since 2003. A substantial increase in the funded
projects occurred between 2005 and 2006 as illustrated in
Figure 2.
Grants to networking projects and clinical trials have
resulted in formation of new networks or support to on-
going ones as illustrated in Figure 3. It is envisaged that
this will increase further in 2008 due to unconditional
funding to regional networks of excellence soon to com-
mence. Please insert a table of list of projects.
After 2006 the DCCC and other EDCTP constituencies
have insisted on demonstration of African leadership and
ownership in the EDCTP programme. Capacity building
programmes have been tremendously supported as
shown in Figure 4. The number of African countries
involved in EDCTP funded projects keep increasing as
illustrated in Figure 5. The next challenge is shaping the
future direction of the organisation.
The future of EDCTP
We have this far argued that EDCTP has a good future as
long as it receives strong support from both African and
European member states in the partnership. As DCCC we
Amount spent on grants in Euros from 2003 to 2008 project  expenditure Figure 1
Amount spent on grants in Euros from 2003 to 2008 
project expenditure.
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propose that the future of EDCTP should include the fol-
lowing elements:
1) Stronger investment for research in the three major
diseases of HIV, TB and malaria
2) Stronger African commitment and leadership
3) Consideration to put European member state fund-
ing into a common pot which currently is not the case
4) Inclusion of basic sciences (discovery research) and
phases I and IV studies in the mandate of EDCTP; con-
solidated in regional networks of excellence
5) Expansion of disease coverage beyond the current
three poverty related diseases to other neglected ones
6) Support for standardisation of methods for evalua-
tion of effectiveness of clinical interventions e.g.
biomarkers and correlates of protection, cure etc
7) Funding drug discovery of traditional medicinal
plants
8) Continued support for regulatory and ethics activi-
ties
Number of capacity building (senior fellowship, SF; Training award, TA; regulatory training and ethics strengthening) activities  granted EDCTP funding from 2005 to 2007 Figure 4
Number of capacity building (senior fellowship, SF; Training award, TA; regulatory training and ethics 
strengthening) activities granted EDCTP funding from 2005 to 2007.
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9) Negotiations with pharmaceutical companies for
third party funding of product research
Some of these points are also contained in the recent
EDCTP independent external evaluation [13]. We believe
that in implementing these recommendations over and
above the current programme, EDCTP will become an
even stronger partner in fighting poverty by improving
health of populations and continue to serve as a best
example of partnerships between developed and least
developed countries in combating regional public health
problems.
Conclusion
Despite facing enormous challenges in its first few years of
existence, EDCTP has succeeded in getting strong involve-
ment of African scientists and, through its new initiatives,
such as unconditional funding to regional networks of
excellence in sub-Saharan Africa, it is envisaged to lead to
a sustainable programme. DCCC proposes that this suc-
cess story of true partnership should be used as model by
partners involved in the fight against other infectious dis-
eases of public health importance in the region.
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